Calidi Biotherapeutics, Inc. Operating Cash Flow
Calidi Biotherapeutics, Inc. (CLDI) reported Operating Cash Flow of -$8.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.35M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.12M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.04M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.24M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$21.29M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$19.69M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$26.98M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$13.21M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$8.47M 10-Q · filed 2026-08-13 | -$13.51M derived: sum of 3 quarters · filed 2026-08-13 | -$17.75M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$4.12M 10-Q · filed 2026-05-14 | -$9.16M derived: sum of 2 quarters · filed 2026-05-14 | -$13.40M derived: sum of 3 quarters · filed 2026-05-14 | -$18.28M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$9.28M derived: sum of 2 quarters · filed 2026-03-27 | -$14.16M derived: sum of 3 quarters · filed 2026-08-13 | -$21.29M 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$4.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$9.12M derived: sum of 2 quarters · filed 2026-08-13 | -$16.25M 10-Q · filed 2025-11-13 | -$21.67M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$12.01M 10-Q · filed 2026-08-13 | -$17.43M derived: sum of 3 quarters · filed 2026-08-13 | -$22.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$7.13M 10-Q · filed 2026-05-14 | -$12.55M derived: sum of 2 quarters · filed 2026-05-14 | -$17.50M derived: sum of 3 quarters · filed 2026-05-14 | -$22.99M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$10.37M derived: sum of 2 quarters · filed 2026-03-27 | -$15.86M derived: sum of 3 quarters · filed 2026-03-27 | -$19.69M 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | -$4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$10.44M derived: sum of 2 quarters · filed 2025-11-13 | -$14.27M 10-Q · filed 2025-11-13 | -$19.46M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$9.32M 10-Q · filed 2025-08-08 | -$14.51M derived: sum of 3 quarters · filed 2025-08-08 | -$28.03M derived: sum of 4 quarters · filed 2025-08-08 | ||||
| 2024-03-31 | -$3.83M 10-Q · filed 2025-05-14 | -$9.02M derived: sum of 2 quarters · filed 2025-05-14 | -$22.53M derived: sum of 3 quarters · filed 2025-05-14 | -$27.71M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$5.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$18.70M derived: sum of 2 quarters · filed 2025-03-31 | -$23.88M derived: sum of 3 quarters · filed 2025-03-31 | -$26.98M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$13.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$18.69M derived: sum of 2 quarters · filed 2024-11-12 | -$21.80M 10-Q · filed 2024-11-12 | -$25.67M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$5.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$8.28M 10-Q · filed 2024-08-13 | $573.78K 10-Q · filed 2023-08-21 | -$12.16M derived: sum of 3 quarters · filed 2024-08-13 | -$20.76M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | -$3.11M 10-Q · filed 2024-05-14 | $192.29K 10-Q · filed 2023-05-15 | -$6.98M derived: sum of 2 quarters · filed 2024-05-14 | -$15.59M derived: sum of 3 quarters · filed 2024-05-14 | -$15.86M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$12.48M derived: sum of 2 quarters · filed 2024-03-15 | -$12.75M derived: sum of 3 quarters · filed 2024-03-15 | -$13.21M 10-K · filed 2024-03-15 | $98.05K 10-K · filed 2023-03-31 | |||
| 2022-09-30 | -$8.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$8.87M derived: sum of 2 quarters · filed 2023-11-14 | -$9.34M 10-Q · filed 2023-11-14 | -$1.07M 10-Q · filed 2022-11-14 | -$8.83M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | -$268.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$733.81K 10-Q · filed 2023-08-21 | -$228.37K derived: sum of 3 quarters · filed 2023-08-21 | -$1.70M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | -$465.13K 10-Q · filed 2023-05-15 | $40.31K derived: sum of 2 quarters · filed 2023-05-15 | -$1.43M derived: sum of 3 quarters · filed 2023-05-15 | -$1.55M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $505.44K derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | -$964.09K derived: sum of 2 quarters · filed 2023-03-31 | -$1.08M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | -$1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | -$1.59M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$118.80K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |